NCT00440427

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

A Randomized, Open-Label, Single-Dose Parallel Group Study of the Pharmacokinetic Profile, Safety, and Tolerability of 25- and 50-mg Desvenlafaxine Sustained Release (DVS SR) in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (planned)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To assess the initial pharmacokinetic profile of single doses of 25mg and 50 mg of DVS SR to healthy subjects.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	Desvenlafaxine Sustained Release (DVS SR)

Timeline

• Start date: 2007-02-01
• Completion: 2007-02-01
• First posted: 2007-02-27
• Last updated: 2007-12-05

Locations

1 site across 1 country: United States